Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) SVP Richard William Scalzo sold 1,343 shares of the company’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $11.38, for a total transaction of $15,283.34. Following the completion of the sale, the senior vice president now directly owns 122,330 shares of the company’s stock, valued at approximately $1,392,115.40. This trade represents a 1.09 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Dyne Therapeutics Stock Performance
Shares of DYN stock opened at $11.88 on Friday. Dyne Therapeutics, Inc. has a fifty-two week low of $11.18 and a fifty-two week high of $47.45. The company has a 50 day moving average price of $15.10 and a 200 day moving average price of $25.73. The stock has a market capitalization of $1.34 billion, a P/E ratio of -3.34 and a beta of 1.11.
Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. On average, research analysts forecast that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Get Our Latest Stock Report on DYN
Hedge Funds Weigh In On Dyne Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in DYN. Quantbot Technologies LP purchased a new stake in shares of Dyne Therapeutics during the third quarter worth approximately $34,000. Point72 DIFC Ltd acquired a new position in Dyne Therapeutics during the 3rd quarter worth approximately $36,000. US Bancorp DE increased its position in shares of Dyne Therapeutics by 776.9% in the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after purchasing an additional 1,212 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Dyne Therapeutics in the 4th quarter valued at $50,000. Finally, KBC Group NV lifted its position in shares of Dyne Therapeutics by 45.3% during the 4th quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after purchasing an additional 978 shares during the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.
About Dyne Therapeutics
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Recommended Stories
- Five stocks we like better than Dyne Therapeutics
- What Are Dividend Achievers? An Introduction
- 3 Undervalued Stocks You Can Buy at a Discount Now
- Market Cap Calculator: How to Calculate Market Cap
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- How Investors Can Find the Best Cheap Dividend Stocks
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.